Divi's Laboratories Limited (DIVISLAB) — key facts
NSE-listed · Healthcare. Data as of 11 Nov 2026 (IST) from InvestSights.
Last close: ₹11,565.5 (+4.22% day change)
Key ratios
- P/E ratio
- 119.54
- P/B ratio
- 9.42
- ROE (%)
- 15.32
- ROCE (%)
- 16.55
- Debt/Equity
- 0
- Dividend yield (%)
- 0.5
- Market cap (₹ Cr)
- 307,027.69
Forensic checks
Piotroski F-Score: 5/9 · Altman Z-Score: 15.09 · Beneish M-Score: -2.39
InvestSights quality score
64.1/100 — Above Average (descriptive data-driven composite; not a recommendation)
Management guidance track record
- Total capital expenditure: guided 2,000Rs Cr, delivered 1,550Rs Cr (H1 FY26) — missed guidance
- Revenue growth: guided 10%, delivered 13.24% (FY26) — exceeded guidance
Latest earnings call (Q1 FY27)
AI summary: The single most important signal from Divi's Q1 FY27 call is the confirmation that all three major dedicated capex projects have completed or are completing validations, with some material already shipped to customers — marking a tangible transition from investment phase to the cusp of commercial supply. The Custom Synthesis segment contributed 60% of standalone revenue, and…
Full analysis on InvestSights
InvestSights is an analytics platform and is not SEBI-registered as a Research Analyst or Investment Adviser. All figures are educational, descriptive data — not investment advice. Consult a SEBI-registered adviser before investing.